Publication Index

Reverse Phase Protein Microarray Publications:

  1. Frederick MJ, Vanmeter AJ, Gadhikar MA, Henderson YC, Yao H, Pickering CC, Williams MD, El-Naggar AK, Sandulache V, Tarco E, Myers JN, Clayman GL, Liotta LA, Petricoin EF 3rd, Calvert VS, Fodale V, Wang J, Weber RS. Phosphoproteomic analysis of signaling pathways in head and neck squamous cell carcinoma patient samples. Am J Pathol. 2011 Feb;178(2):548-71.
  2. Pilie PG, Ibarra-Drendall C, Troch MM, Broadwater G, Barry WT, Petricoin EF 3rd, Wulfkuhle JD, Liotta LA, Lem S, Baker JC Jr, Stouder A, Ford AC, Wilke LG, Zalles CM, Mehta P, Williams J, Shivraj M, Su Z, Geradts J, Yu D, Seewaldt VL. Protein Microarray Analysis of Mammary Epithelial Cells from Obese and Non-Obese Women at High Risk for Breast Cancer: Feasibility Data. Cancer Epidemiol Biomarkers Prev. 2011 Jan 17.
  3. Younossi ZM, Limongi D, Stepanova M, Pierobon M, Afendy A, Mehta R, Baranova A, Liotta L, Petricoin E. Protein Pathway Activation Associated with Sustained Virologic Response in Patients with Chronic Hepatitis C Treated with Pegylated Interferon (PEG-IFN) and Ribavirin (RBV). J Proteome Res. 2011 Jan 4. [Epub ahead of print]
  4. Maraldi T, Bertacchini J, Benincasa M, Guida M, De Pol A, Liotta LA, Petricoin E 3rd, Cocco L, Marmiroli S. Reverse-phase protein microarrays (RPPA) as a diagnostic and therapeutic guide in multidrug resistant leukemia. Int J Oncol. 2011 Feb;38(2):427-35.
  5. Georgitsi M, Viennas E, Antoniou DI, Gkantouna V, van Baal S, Petricoin EF 3rd, Poulas K, Tzimas G, Patrinos GP. FINDbase: a worldwide database for genetic variation allele frequencies updated. Nucleic Acids Res. 2011 Jan;39(Database issue):D926-32.
  6. Matei D, Sill MW, Lankes HA, Degeest K, Bristow RE, Mutch D, Yamada SD, Cohn D, Calvert V, Farley J, Petricoin EF, Birrer MJ. Activity of Sorafenib in Recurrent Ovarian Cancer and Primary Peritoneal Carcinomatosis: A Gynecologic Oncology Group Trial. J Clin Oncol. 2011 Jan 1;29(1):69-75.
  7. Longo C, Gambara G, Espina V, Luchini A, Bishop B, Patanarut AS, Petricoin EF 3rd, Beretti F, Ferrari B, Garaci E, De Pol A, Pellacani G, Liotta LAA novel biomarker harvesting nanotechnology identifies Bak as a candidate melanoma biomarker in serum. Exp Dermatol. 2011 Jan;20(1):29-34
  8. Wilson B, Liotta LA, Petricoin E 3rd. Monitoring proteins and protein networks using reverse phase protein arrays. Dis Markers. 2010;28(4):225-32.
  9. Younossi Z, Baranova A, Stepanova M, Page S, Calvert V, Afendy A, Goodman Z, Chandhoke V, Liotta L, Petricoin E. Phosphoproteomics Biomarkers Predicting Non-alcoholic Steatohepatitis and Fibrosis. J Proteome Res. 2010 May 4.
  10. Espina V, Mariani BD, Gallagher RI, Tran K, Banks S, Wiedemann J, Huryk H, Mueller C, Adamo L, Deng J, Petricoin EF, Pastore L, Zaman S, Menezes G, Mize J, Johal J, Edmiston K, Liotta LA. Malignant precursor cells pre-exist in human breast DCIS and require autophagy for survival. PLoS One. 2010 Apr 20;5(4):e10240.
  11. Silvestri A, Colombatti A, Calvert VS, Deng J, Mammano E, Belluco C, De Marchi F, Nitti D, Liotta LA, Petricoin EF, Pierobon M. Protein pathway biomarker analysis of human cancer reveals requirement for upfront cellular-enrichment processing. Lab Invest. 2010 May;90(5):787-96.
  12. Wei BH,. Hoover SB, Ross MR, Zhou W, Meani F, Edwards JB, Spehalski EI, Risinger JI, Alvord WG, Quiñones OA, Belluco C, Martella, Campagnutta E, Ravaggi A, Dai RM, Goldsmith PK, Woolard KD, Pecorelli S, Liotta LA, Petricoin EF, Simpson RM. S100A6 Concentration Predicts Peritoneal Tumor Burden in Mice with Epithelial Ovarian Cancer and Is Associated with Advanced Stage in Patients. PloS One. 2009 Oct 30;4(10):e7670.
  13. Anderson T, Wulfkuhle J, Liotta L, Winslow RL, Petricoin E 3rd. Improved reproducibility of reverse phase protein microarrays using array microenvironment normalization” Proteomics. 2009 Oct 15. [Epub ahead of print]
  14. Finley DS, Calvert VS, Inokuchi J, Lau A, Narula N, Petricoin EF, Zaldivar F, Santos R, Tyson DR, Ornstein DK. Periprostatic Adipose Tissue as a Modulator of Prostate Cancer Aggressiveness. J Urol. 2009 Aug 15.
  15. Davuluri G, Espina V, Petricoin EF 3rd, Ross M, Deng J, Liotta LA, Glaser BM. Activated VEGF Receptor Shed Into the Vitreous in Eyes With Wet AMD: A New Class of Biomarkers in the Vitreous With Potential for Predicting the Treatment Timing and Monitoring Response. Arch Ophthalmol. 2009 May;127(5):613-21.
  16. Pierobon M, Calvert V, Belluco C, Garaci E, Deng J, Lise M, Nitti D, Mammano E, Marchi FD, Liotta L, Petricoin E. Multiplexed Cell Signaling Analysis of Metastatic and Nonmetastatic Colorectal Cancer Reveals COX2-EGFR Signaling Activation as a Potential Prognostic Pathway Biomarker. Clin Colorectal Cancer. 2009 Apr;8(2):110-7.
  17. Popova T, Espina VE, Bailey C, Liotta L, Petricoin E, Popov S. Anthrax infection inhibits the AKT signaling involved in the E-cadherin-mediated adhesion of lung epithelial cells FEMS Immuol Med Microbiol. 2009 April E pub ahead of print
  18. Gulmann C, Sheehan KM, Conroy RM, Wulfkuhle JD, Espina V, Mullarkey MJ, Kay EW, Liotta LA, Petricoin EF. Quantitative cell signallng analysis reveals down-regulation of MAPK pathway activation in colorectal cancer. J Pathol. 2009 Mar 20.
  19. Petricoin EF.Proteomics in laboratory medicine. Preface. Clin Lab Med. 2009 Mar;29(1):xiii-xiv.
  20. Espina V, Liotta LA, Petricoin EF. Reverse-phase protein microarrays for theranostics and patient tailored therapy. Methods Mol Biol. 2009;520:89-105.
  21. Grubb R, Deng J, Pinto P, Mohler J, Chinnaiyan A, Rubin M, Linehan W, Liotta L, Petricoin EF, Wulfkuhle J.Pathway Biomarker Profiling of Localized and Metastatic Human Prostate Cancer Reveal Metastatic and Prognostic Signatures. J Proteome Res. 2009 Mar 10. [Epub ahead of print].
  22. Nijdam AJ, Zianni MR, Herderick EE, Cheng MM, Prosperi JR, Robertson FA, Petricoin EF, Liotta LA, Ferrari M Application of Physicochemically Modified Silicon Substrates as Reverse-Phase Protein Microarrays.J Proteome Res. 2009 Jan 26
  23. Vanmeter AJ, Rodriguez AS, Bowman ED, Harris CC, Deng J, Calvert VS, Silvestri A, Fredolini C, Chandhoke V, Petricoin EF 3rd, Liotta LA, Espina V.LCM and protein microarray analysis of human NSCLC: Differential EGFR phosphorylation events associated with mutated EGFR compared to wild type. Mol Cell Proteomics. 2008 Oct;7(10):1902-24.
  24. Espina VA, Edmiston KH, Heiby M, Pierobon M, Sciro M, Merritt B, Banks S, Deng J, Vanmeter AJ, Geho DH, Pastore L, Sennesh J, Petricoin EF 3rd, Liotta LA. A portrait of tissue phosphoprotein stability in the clinical tissue procurement process. Mol Cell Proteomics. 2008 Oct;7(10):1998-2018.
  25. Speer R, Wulfkuhle J, Espina V, Aurajo R, Edmiston KH, Liotta LA, Petricoin EF 3rd.Molecular network analysis using reverse phase protein microarrays for patient tailored therapy. Adv Exp Med Biol. 2008;610:177-86.
  26. Liotta L, Petricoin E.Nanomedicine–the power of proteins: a conversation with Lance Liotta and Emanual Petricoin. Interview by Barbara J Culliton. Health Aff. 2008 Jul-Aug;27(4):w310-4.
  27. Espina V, Wulfkuhle J, Calvert VS, Liotta LA, Petricoin EF 3rd. Reverse phase protein microarrays for theranostics and patient-tailored therapy. Methods Mol Biol. 2008;441:113-28.
  28. Wulfkuhle JD, Speer R, Pierobon M, Laird J, Espina V, Deng Jm Mammano E, Yang SX, Swain SM, Nitti D, Esserman LJ, Belluco C, Liotta LA and Petricoin EF. Multiplexed Cell Signaling Analysis of Human Breast Cancer: Applications for Personalized Therapy. J of Prot Res. 2008 Apr;7(4):1508-17.
  29. Espina V, Wulfkuhle JD, Calvert VS, Petricoin EF 3rd, Liotta LA. Reverse phase protein microarrays for monitoring biological responses. Methods Mol Biol. 2007;383:321-36.
  30. Sanchez-Carbayo M, Socci ND, Richstone L, Corton M, Behrendt N, Wulkfuhle J, Bochner B, Petricoin E, Cordon-Cardo C. Genomic and Proteomic Profiles Reveal the Association of Gelsolin to TP53 Status and Bladder Cancer Progression. Am J Pathol. 2007 Nov;171(5):1650-1658.
  31. Zhou, J, Wulfkuhle J, Zhang H, Gu P, Yang Y, Deng J, Margolick JB, Liotta LA, Petricoin EF, Zhang Y. Activation of the PTEN/mTOR/STAT3 pathway in breast cancer stem-like cells is required for viability and maintenance. PNAS 2007. Oct 9;104(41):16158-63.
  32. VanMeter A, Signore M, Pierobon M, Espina V, Liotta LA, Petricoin EF Reverse-phase protein microarrays: application to biomarker discovery and translational medicine Expert Review of Molecular Diagnostics. 2007. 7(5): 625-633(9)
  33. Speer R, Wulfkuhle J, Espina V, Aurajo R, Edmiston KH, Liotta LA, Petricoin EF 3rd. Development of reverse phase protein microarrays for clinical applications and patient-tailored therapy. Cancer Genomics Proteomics. 2007 May-Jun;4(3):157-64.
  34. Sheehan KM, Gulmann, C, Eichler GS, Weinstein, J, Barrett HL, Kay EW, Conroy RM, Liotta LA, Petricoin EF, Signal Pathway Profiling of Epithelial and Stromal Compartments of Colonic Carcinoma Reveal Epithelial-Mesenchymal Transition Oncogene, 2007 July 9 epub ahead of print.
  35. Araujo RP, Petricoin EF, Lotta LA.: Mathematical modeling of the cancer cell’s control circuitry: Paving the way to patient-tailored combination therapy. Current Signal Transduction Therapies, 2007. 2(2):145-55.
  36. Rapkiewicz A, Espina V, Zujewski JA, Lebowitz PF, Filie A, Wulfkuhle J, Camphausen K, Petricoin EF 3rd, Liotta LA, Abati A. The needle in the haystack: Application of breast fine-needle aspirate samples to quantitative protein microarray technology. Cancer Cytology. 2007 May 8; [Epub ahead of print
  37. Petricoin EF, Espina V, Araujo RP, Midura B, Yeung C, Wan X, Eichler GS, Johann DJ,Qualman, S, Tsokos M, Krishnan K, Helman LJ, Liotta LA. Phosphoprotein Signal Pathway Mapping: Akt/mTOR Pathway Activation Association with Childhood Rhabdomyosarcoma Survival. Cancer Research. 2007;67(7):3431–4
  38. Calvert VS, Collantes R, Elariny H, Afendy A, Baranova A, Mendoza M, Goodman Z, Liotta LA, Petricoin EF, and Younossi ZM. A Systems Biology Approach to the Pathogenesis of Non-Alcoholic Fatty Liver Disease (NAFLD): Molecular Network Analysis of Human Adipose Tissue Can Distinguish Non-alcoholic Steatohepatitis (NASH) from Non-Progressive Simple Steatosis. Hepatology. 2007. 46(1) 166-172.
  39. Shankavaram UT, Reinhold WC, Nishizuka S, Major S, Morita D, Chary KK, Reimers MA, Scherf U, Kahn A, Dolginow D, Cossman J, Kaldjian EP, Scudiero DA, Petricoin E, Liotta L, Lee JK, Weinstein JN. Transcript and protein expression profiles of the NCI-60 cancer cell panel: an integromic microarray study. Mol Cancer Ther. 2007 Mar;6(3):820-32
  40. VanMeter A, Calvert VS., Wulfkuhle JD., Petricoin EF, Liotta LA., Espina V. Qualification of Microarrayers for Clinical Research, BioRadiations. 2007. February 1.
  41. Nijdam AJ, Ming-Cheng Cheng M, Geho DH, Fedele R, Herrmann P, Killian K, Espina V, Petricoin EF 3rd, Liotta LA, Ferrari M. Physicochemically modified silicon as a substrate for protein microarrays. Biomaterials. 2006 Sep 18 [Epub ahead of print]
  42. Geho D., Garaci E., Petricoin E., Cooper J., Espina V. and Liotta L. Proteomics and personalized medicine. Personalized Medicine, 2006 3(3): 223-226.
  43. Campbell MJ, Esserman LJ, Zhou Y, Shoemaker M, Lobo M, Borman E, Baehner F, Kumar AS, Adduci K, Marx C, Petricoin EF, Liotta LA, Winters M, Benz S, and Benz CC. Breast cancer growth prevention by statins. Cancer Res. 2006 Sep 1;66(17):8707-14.
  44. Wulfkuhle JD, Edmiston KH, Liotta LA, Petricoin EF. Technology Insight: pharmacoproteomics for cancer-promises of patient-tailored medicine using protein microarrays. Nat Clin Pract Oncol. 2006 May;3(5):256-68.
  45. Gulmann C, Sheehan K, Kay E, Liotta L, Petricoin E 3rd. Array-based proteomics: mapping of protein circuitries for diagnostics, prognostics, and therapy guidance in cancer. J Pathol. 2006 Mar 3;208(5):595-606
  46. Conrads TP, Hood BL, Petricoin EF, Liotta LA, Veenstra TD. Cancer proteomics: many technologies, one goal. Expert Rev Proteomics. 2005 Oct;2(5):693-703.
  47. Geho DH, Petricoin EF, Liotta LA, Araujo RP. Modeling of protein signaling networks in clinical proteomics. Cold Spring Harb Symp Quant Biol. 2005;70:517-24.
  48. Gulmann C, Espina V, Petricoin E, Longo, DL, Santi M, Knutsen T, Raffeld M, Jaffe ES, Liotta LA, Feldman AL. Proteomic analysis of apoptotic pathways reveal prognostic factors in follicular lymphoma. Clinical Cancer Research 2005 Aug 15;11(16):5847-55.
  49. Speer R, Wulfkuhle JD, Liotta LA. Petricoin EF. Reverse-phase protein microarrays for tissue-based analysis. Curr Opin Mol Ther. 2005 Jun;7(3):240-5.
  50. Belluco C, Mammano E, Petricoin E, Prevedello L, Calvert V, Liotta L, Nitti D, Lise M. Kinase substrate protein microarray analysis of human colon cancer and hepatic metastasis. Clin Chim Acta. 2005 May 24; [Epub ahead of print]
  51. Petricoin EF 3rd, Bichsel VE, Calvert VS, Espina V, Winters M, Young L, Belluco C, Trock BJ, Lippman M, Fishman DA, Sgroi DC, Munson PJ, Esserman LJ, Liotta LA. Mapping molecular networks using proteomics: a vision for patient-tailored combination therapy. J Clin Oncol. 2005 May 20;23(15):3614-21.
  52. Geho D, Lahar N, Gurnani P, Huebschman M, Herrmann P, Espina V, Shi A, Wulfkuhle J, Garner H, Petricoin E 3rd, Liotta LA, Rosenblatt KP. Pegylated, Steptavidin-Conjugated Quantum Dots Are Effective Detection Elements for Reverse-Phase Protein Microarrays. Bioconjug Chem. 2005 May 18;16(3):559-566.
  53. Winters ME, Mehta AI, Petricoin EF 3rd, Kohn EC, Liotta LA. Supra-additive growth inhibition by a celecoxib analogue and carboxyamido-triazole is primarily mediated through apoptosis. Cancer Res. 2005 May 1;65(9):3853-60
  54. Iyengar P, Espina V, Williams TW, Lin Y, Berry D, Jelicks LA, Lee H, Temple K, Graves R, Pollard J, Chopra N, Russell RG, Sasisekharan R, Trock BJ, Lippman M, Calvert VS, Petricoin EF, Liotta L, Dadachova E, Pestell RG, Lisanti MP, Bonaldo P, Scherer PE. Adipocyte-derived collagen VI affects early mammary tumor progression in vivo, demonstrating a critical interaction in the tumor/stroma microenvironment. J Clin Invest. 2005 May 2;115(5):1163-1176.
  55. Espina V, Geho D, Mehta AI, Petricoin EF 3rd, Liotta LA, Rosenblatt KP. Pathology of the future: molecular profiling for targeted therapy. Cancer Invest. 2005;23(1):36-46.
  56. Calvo KR, Liotta LA, Petricoin EF. Clinical proteomics: from biomarker discovery and cell signaling profiles to individualized personal therapy. Biosci Rep. 2005 Feb-Apr;25(1-2):107-25.
  57. Sheehan KM, Calvert VS, Kay EW, Lu Y, Fishman D, Espina V, Aquino J, Speer R, Araujo R, Mills GB, Liotta LA, Petricoin EF 3rd, Wulfkuhle JD. Use of reverse phase protein microarrays and reference standard development for molecular network analysis of metastatic ovarian carcinoma. Mol Cell Proteomics. 2005 Apr;4(4):346-55. Epub 2005 Jan 25.
  58. Cowherd SM, Espina VA, Petricoin EF 3rd, Liotta LA. Proteomic analysis of human breast cancer tissue with laser-capture microdissection and reverse-phase protein microarrays. Clin Breast Cancer. 2004 Dec;5(5):385-92.
  59. Wulfkuhle J, Espina V, Liotta L, Petricoin E. Genomic and proteomic technologies for individualisation and improvement of cancer treatment. Eur J Cancer. 2004 Nov;40(17):2623-32.
  60. Krieg RC, Knuechel R, Schiffmann E, Liotta LA, Petricoin EF 3rd, Herrmann PC. Mitochondrial proteome: cancer-altered metabolism associated with cytochrome c oxidase subunit level variation. Proteomics. 2004 Sep;4(9):2789-95.
  61. Espina V, Woodhouse EC, Wulfkuhle J, Asmussen HD, Petricoin EF 3rd, Liotta LA. Protein microarray detection strategies: focus on direct detection technologies. J Immunol Methods. 2004 Jul;290(1-2):121-33.
  62. Espina V, Woodhouse EC, Wulfkuhle J, Asmussen HD, Petricoin EF 3rd, and Liotta LA. Protein microarray detection strategies: Focus on direct detection technologies. J Immunol Methods. 2004 Jul;290(1-2):121-33.
  63. Roberts E, Charboneau L, Espina V, Liotta L, Petricoin E, and Dreher K. Application of laser capture microdissection and protein microarray technologies in the molecular analysis of airway injury following pollution particle exposure. J Toxicol Environ Health A. 2004 Jun 11;67(11):851-61.
  64. Ornstein DK, and Petricoin EF 3rd. Proteomics to diagnose human tumors and provide prognostic information. Oncology. 2004 Apr;18(4):521-9; discussion 529-32.
  65. Petricoin E, Wulfkuhle J, Espina V, and Liotta LA. Clinical proteomics: Revolutionizing disease detection and patient tailoring therapy. J Proteome Res. 2004 Mar-Apr;3(2):209-17.
  66. Calvert VS, Tang Y, Boveia V, Wulfkuhle J, Schutz-Geschwender Olive DM, Liotta LA, Petricoin EF Development of Multiplexed Protein Profiling and Detection Using Near Infrared Detection of Reverse-Phase Protein Microarrays Clinical Proteomics 2004 1(1) 81-90.
  67. Espina V, Petricoin EF, Liotta LA, Geho D Application of Sector Protein Microarrays to Clinical Samples Clinical Proteomics 2004 1(1) 91-100.
  68. Hasan RK, Wulfkuhle JD, Liotta LA, and Petricoin EF. Molecular technologies for personalized cancer management. JAMA. 2004 Apr 7;291(13):1644-5.
  69. Zha H, Raffeld M, Charboneau L, Pittaluga S, Kwak LW, Petricoin E, Liotta LA and Jaffe ES. Similarities of prosurvival signals in Bcl-2-positive and Bcl-2-negative follicular lymphomas identified by reverse phase protein microarray. J Lab Invest. 2004 Feb;84(2):235-44.
  70. Berman DM, Shih IM, Burke LA, Veenstra TD, Zhao Y, Conrads TP, Kwon SW, Hoang V, Yu LR, Zhou M, Kurman RJ, Petricoin EF, and Liotta LA. Profiling the activity of G proteins in patient-derived tissues by rapid affinity-capture of signal transduction proteins (GRASP). Proteomics. 2004 Mar;4(3):812-8.
  71. Herrmann PC, Gillespie JW, Charboneau L, Bichsel VE, Paweletz CP, Calvert VS, Kohn EC, Emmert-Buck MR, Liotta LA, and Petricoin EF 3rd. Mitochondrial proteome: Altered cytochrome c oxidase subunit levels in prostate cancer. Proteomics. 2003 Sep;3(9):1801-10.
  72. Woodhouse EC, Fisher A, Bandle RW, Bryant-Greenwood B, Charboneau L, Petricoin EF 3rd, and Liotta LA. Drosophila screening model for metastasis: Semaphorin 5c is required for l(2)gl cancer phenotype. Proc Natl Acad Sci. 2003 Sep 30;100(20):11463-8.
  73. Wulfkuhle JD, Paweletz CP, Steeg PS, Petricoin EF, and Liotta LA. Proteomic approaches to the diagnosis, treatment, and monitoring of cancer. Adv Exp Med Biol. 2003 532:59-68.
  74. Espina V, Mehta AI, Winters ME, Wulfkuhle J, Petricoin EF, and Liotta LA. Protein microarrays: Molecular profiling technologies for clinical specimens. Proteomics. 2003 Nov;3(11):2091-100.
  75. Grubb RL, Calvert VS, Paweletz CP, Phillips JL, Linehan WM, Gillespie JW, Emmert-Buck MR, Liotta L, and Petricoin EF. Signal pathway profiling of prostate cancer using reverse phase protein arrays. Proteomics. 2003 Nov;3(11):2142-6.
  76. Wulfkuhle JD., Aquino JA, Calvert VS, Fishman DA, Coukos G, Liotta LA, and Petricoin EF. Signal pathway profiling of ovarian cancer from human tissue specimens using reverse-phase microarrays. Proteomics. 2003 Nov;3(11):2085-90.
  77. Nishizuka S, Charboneau L, Young L, Major S, Reinhold WC, Waltham M, Kouros-Mehr H, Bussey KJ, Lee JK, Munson PJ, Petricoin EF, Liotta LA, and Weinstein JN. Diagnostic markers that distinguish colon and ovarian adenocarcinomas: Identification by genomic, proteomic, and tissue array profiling. Cancer Research. 2003 Sep 1;63(17):5243-50.
  78. Nishizuka S, Charboneau L,Young L, Major S, Reinhold WC, Waltham M, Kouros-Mehr H, Bussey KL, Lee JK, Munson PJ, Petricoin III EF, Liotta LA, and Weinstein JN. Proteomic profiling of the NCI60 cancer cell lines using new high-density ‘reverse-phase’ lysate microarrays. Proc. Natl Acad Sci. 2003 Nov 25;100(24):14229-34.
  79. Herrmann PC, Gillespie JW, Charboneau L, Bichsel VE, Paweletz CP, Calvert VS, Kohn EC, Emmert-Buck MR, Liotta LA, and Petricoin EF. Mitochondrial proteome: Altered cytochrome c oxidase subunit levels in prostate cancer. Proteomics. 2003 Sep;3(9):1801-10.
  80. Barrett JC, Bennett LM, Fleming LK, Linehan WM, Liotta LA, Rosenberg SA, Petricoin EF 3rd, Staudt LM, Thompson TE, Yang JC. Linking laboratory and clinical research: the development of molecularly targeted therapeutics inside the national cancer institute center for cancer research. Clin Adv Hematol Oncol. 2003 May;1(5):302-6.
  81. Liotta LA, Espina V, Mehta AI, Calvert V, Rosenblatt K, Geho D, Munson PJ, Young L, Wulfkuhle J, and Petricoin EF. Protein microarrays: Meeting analytical challenges for clinical applications. Cancer Cell. 2003 Apr;3(4):317-25.
  82. Petricoin, E.F., Zoon, K.C., Kohn, E.C., Barrett, J.C., and Liotta, L.A. Clinical proteomics: Translating benchside promise into bedside reality. Nature Rev. Drug Disc. 2002 Sep;1(9):683-95.
  83. Liotta, L.A., and Petricoin, E.F. Serum proteomic pattern diagnostics for ovarian
  84. Charboneau L, Scott H, Chen T, Winters M, Petricoin EF 3rd, Liotta LA, and Paweletz CP. Technique review: Utility of reverse phase protein arrays: Applications to signalling pathways and human body arrays. Brief Funct Genomic Proteomic. 2002 Oct;1(3):305-15.
  85. Charboneau, L., Scott, H., Chen, T., Winters, M., Petricoin III, E.F., Liotta, L.A., and Paweletz, C. Utility of reverse phase portien arrays: Applications to signaling pathways and human body arrays. Briefings in Functional Genomics and Proteomics. 2002 Oct;1(3):305-15.
  86. Paweletz CP, Charboneau L, Roth MJ, Bichsel VE, Simone NL, Chen T, Han N, Gillespie JW, Emmert-Buck M, Petricoin EF, and Liotta LA. Reverse phase proteomic microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front. Oncogene. 2001 Apr 12;20(16):1981-9.